News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Why Eli Lilly and Company (LLY) May Never Get Bought By Valeant Pharmaceuticals International (VRX) -- Or Anyone Else


6/25/2014 6:52:06 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

With its $67 billion market capitalization — about a third that of Pfizer or Merck — Indianapolis-based Eli Lilly often gets mentioned as a buyout candidate. But it will probably never get bought out. The reason, as Sanford C. Bernstein analyst Timothy Anderson explains in a note to investors this morning, is the state law in Indiana.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES